Mechanisms of Metabolic Vasodilation
代谢性血管舒张机制
基本信息
- 批准号:7191656
- 负责人:
- 金额:$ 29.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2004
- 资助国家:美国
- 起止时间:2004-03-05 至 2009-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdenosineAgonistAnimalsAreaArginineBlood VesselsBlood flowCalciumCaliberCellsCharacteristicsCommunicationConditionConfocal MicroscopyContractsCoupledCouplingElectrodesEndothelial CellsExerciseGoalsHealthHumanIschemiaKnockout MiceLiteratureMetabolicMinorModelingMusMuscle ContractionNitric OxidePathway interactionsPerfusionPhysiologicalPreparationProductionProstaglandinsProtocols documentationRateRegulationResistanceRoleSignal PathwaySignal TransductionSkeletal MuscleSkeletal systemSmooth Muscle MyocytesSourceStriated MusclesTestingThapsigarginTissuesVasodilationVasodilator AgentsWorkarteriolebasecremaster muscleextracellularlatent nuclear antigenparacrineresponse
项目摘要
Regulation of blood flow and metabolic rate are closely coupled in striated muscle, but the pathways that specifically enable vasoactive metabolites to produce integrated arteriolar responses remain elusive. We have identified endothelial cells (EC), and EC Ca 2+ changes, as essential for metabolic vasodilation in resistance arterioles. This dilation involves, KATP channels, nitric oxide and adenosine, but how KATP channel activity relates to the actions of NO and adenosine is not clear. Importantly, the contribution of NO to this dilation is most prominent in ischemic conditions, i.e. mechanisms of metabolic vasodilation are modified by flow. The studies will use cremaster muscle of anesthetised mice to determine the mechanisms of this response in free flow and ischemic conditions. Intravital confocal microscopy will be used to quantify EC Ca 2+ and arteriolar diameter changes during skeletal muscle contraction. We will test 3 hypotheses that are based on our preliminary findings. Hyp. I: In metabofic vasodilation, KATP channels are required for the production of EC Ca 2+ changes. Hyp. Il: EC Ca 2+ changes are essential for metabolic vasodilation in all flow conditions. These changes consist of two components - an early increase mobilised from intracellular stores, and an oscillatory component dependent on extracellular calcium sources. Hyp. IIl: (Part A) NO of endothelial origin contributes significantly to the metabolic vasodilation that occurs during ischemic conditions, but is a much less important component of the response during free flow. (Part B) NO from non-endothelially located nNOS also contributes to metabofic vasodilation (particularly during ischemia) both by a direct effect on SMCs and by stimulating release of NO from endothelial cells. The studies will contribute to the general understanding of how local responses to physiological signals are integrated in blood vessel walls, and will contribute significantly to the broad goal of understanding the metabolic response to exercise. A full understanding of the mechanisms underlying exercise is relevant to many areas of human health.
在横纹肌中,血流量和代谢率的调节是密切相关的,但具体使血管活性代谢物产生综合小动脉反应的途径仍然难以捉摸。我们已经确定内皮细胞(EC)和EC ca2 +的变化,是抵抗性小动脉代谢血管舒张的必要条件。这种扩张涉及到KATP通道、一氧化氮和腺苷,但KATP通道活性如何与NO和腺苷的作用相关尚不清楚。重要的是,一氧化氮对这种扩张的贡献在缺血条件下最为突出,即代谢血管舒张的机制被血流改变。该研究将使用麻醉小鼠的肌肌来确定这种反应在自由流动和缺血条件下的机制。活体共聚焦显微镜将用于量化EC ca2 +和骨骼肌收缩期间小动脉直径的变化。我们将测试基于我们初步发现的3个假设。hypp . I:在代谢性血管扩张中,KATP通道是产生EC ca2 +变化所必需的。Hyp. Il: EC ca2 +的变化对所有血流条件下的代谢性血管舒张是必不可少的。这些变化包括两个组成部分-细胞内储存的早期增加和依赖于细胞外钙源的振荡成分。Hyp. il:(A部分)内皮细胞来源的NO对缺血性条件下发生的代谢性血管舒张有重要贡献,但在自由血流反应中则不太重要。(B部分)来自非内皮细胞nNOS的NO也有助于代谢性血管舒张(特别是在缺血期间),这是通过直接作用于SMCs和刺激内皮细胞释放NO来实现的。这些研究将有助于了解局部对生理信号的反应如何整合到血管壁中,并将对理解运动代谢反应的广泛目标做出重大贡献。充分了解运动背后的机制与人类健康的许多领域有关。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
INGRID H SARELIUS其他文献
INGRID H SARELIUS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('INGRID H SARELIUS', 18)}}的其他基金
相似国自然基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
- 批准号:82074359
- 批准年份:2020
- 资助金额:55 万元
- 项目类别:面上项目
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
- 批准号:81570244
- 批准年份:2015
- 资助金额:57.0 万元
- 项目类别:面上项目
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制
- 批准号:81171113
- 批准年份:2011
- 资助金额:55.0 万元
- 项目类别:面上项目
相似海外基金
Development of an adenosine A1 receptors agonist, MRS5474 for the treatment of chronic depression
开发用于治疗慢性抑郁症的腺苷 A1 受体激动剂 MRS5474
- 批准号:
10220705 - 财政年份:2018
- 资助金额:
$ 29.87万 - 项目类别:
Development of an adenosine A1 receptors agonist, MRS5474 for the treatment of chronic depression
开发用于治疗慢性抑郁症的腺苷 A1 受体激动剂 MRS5474
- 批准号:
9797678 - 财政年份:2018
- 资助金额:
$ 29.87万 - 项目类别:
Prevention of Lung Transplant Injury with Adenosine 2A Receptor Agonist
腺苷2A受体激动剂预防肺移植损伤
- 批准号:
9053014 - 财政年份:2016
- 资助金额:
$ 29.87万 - 项目类别:
Adenosine 2A Receptor Agonist in Diabetic Nephropathy
腺苷 2A 受体激动剂治疗糖尿病肾病
- 批准号:
7993837 - 财政年份:2009
- 资助金额:
$ 29.87万 - 项目类别:
Adenosine 2A Receptor Agonist in Diabetic Nephropathy
腺苷 2A 受体激动剂治疗糖尿病肾病
- 批准号:
7455287 - 财政年份:2007
- 资助金额:
$ 29.87万 - 项目类别:
Adenosine 2A Receptor Agonist in Diabetic Nephropathy
腺苷 2A 受体激动剂治疗糖尿病肾病
- 批准号:
7895818 - 财政年份:2007
- 资助金额:
$ 29.87万 - 项目类别:
Adenosine 2A Receptor Agonist in Diabetic Nephropathy
腺苷 2A 受体激动剂治疗糖尿病肾病
- 批准号:
7624687 - 财政年份:2007
- 资助金额:
$ 29.87万 - 项目类别:
Adenosine 2A Receptor Agonist in Diabetic Nephropathy
腺苷 2A 受体激动剂治疗糖尿病肾病
- 批准号:
8111822 - 财政年份:2007
- 资助金额:
$ 29.87万 - 项目类别:
Safety of A2A Adenosine Agonist for Treatment of Sepsis
A2A 腺苷激动剂治疗脓毒症的安全性
- 批准号:
7108075 - 财政年份:2006
- 资助金额:
$ 29.87万 - 项目类别:
Safety of Adenosine A2a Agonist for Treatment of Sepsis
腺苷 A2a 激动剂治疗脓毒症的安全性
- 批准号:
7247106 - 财政年份:2006
- 资助金额:
$ 29.87万 - 项目类别:














{{item.name}}会员




